Literature DB >> 28851089

Comparison of the performance in detection of HPV infections between the high-risk HPV genotyping real time PCR and the PCR-reverse dot blot assays.

Lahong Zhang1, Yibei Dai2, Jiahuan Chen1, Liquan Hong1, Yuhua Liu1, Qiang Ke1, Yiwen Chen3, Chengsong Cai1, Xia Liu1, Zhaojun Chen1.   

Abstract

A new multiplex real-time PCR assay, the high-risk HPV genotyping real time PCR assay (HR HPV RT-PCR), has been developed to detect 15 high-risk HPV types with respective viral loads. In this report, a total of 684 cervical specimens from women diagnosed with vaginitis were assessed by the HR HPV RT-PCR and the PCR reaction and reverse dot blot (PCR-RDB) assays, using a PCR-sequencing method as a reference standard. A total coincidence of 97.7% between the HR HPV RT PCR and the PCR-RDB assays was determined with a Kappa value of 0.953. The HR HPV RT PCR assay had sensitivity, specificity, and concordance rates (accuracy) of 99.7%, 99.7%, and 99.7%, respectively, as confirmed by PCR-sequencing, while the PCR-RDB assay had respective rates of 98.8%, 97.1%, and 98.0%. The overall rate of HPV infection, determined by PCR-sequencing, in women diagnosed with vaginitis was 49.85%, including 36.26% of single infection and 13.6% of multiple infections. The most common infections among the 15 high-risk HPV types in women diagnosed with vaginitis were HPV-52, HPV-16, and HPV-58, with a total detection rate of 10.23%, 7.75%, and 5.85%, respectively. We conclude that the HR HPV RT PCR assay exhibits better clinical performance than the PCR-RDB assay, and is an ideal alternative method for HPV genotyping. In addition, the HR HPV RT PCR assay provides HPV DNA viral loads, and could serve as a quantitative marker in the diagnosis and treatment of single and multiple HPV infections.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  PCR-reverse dot blot assay; high-risk HPV genotyping real time PCR assay; human papilloma virus (HPV); sequencing

Mesh:

Substances:

Year:  2017        PMID: 28851089     DOI: 10.1002/jmv.24931

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study.

Authors:  Binhua Dong; Lihua Chen; Wenyu Lin; Yingying Su; Xiaodan Mao; Diling Pan; Guanyu Ruan; Huifeng Xue; Yafang Kang; Pengming Sun
Journal:  Cancer Cell Int       Date:  2020-08-28       Impact factor: 5.722

2.  Human papillomavirus genotype prevalence in the women of Shanghai, China and its association with the severity of cervical neoplasia.

Authors:  Jingbo Wu; Xiaojing Li; Xiuping Liu; Zuhua Gao
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

3.  Effect of introducing human papillomavirus genotyping into real-world screening on cervical cancer screening in China: a retrospective population-based cohort study.

Authors:  Binhua Dong; Huachun Zou; Xiaodan Mao; Yingying Su; Hangjing Gao; Fang Xie; Yuchun Lv; Yaojia Chen; Yafang Kang; Huifeng Xue; Diling Pan; Pengming Sun
Journal:  Ther Adv Med Oncol       Date:  2021-04-28       Impact factor: 8.168

Review 4.  Recent advances in lab-on-a-chip technologies for viral diagnosis.

Authors:  Hanliang Zhu; Zdenka Fohlerová; Jan Pekárek; Evgenia Basova; Pavel Neužil
Journal:  Biosens Bioelectron       Date:  2020-01-22       Impact factor: 10.618

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.